Core Insights - JD Health and Boehringer Ingelheim Animal Health (Shanghai) Co., Ltd. signed a strategic cooperation agreement to enhance the pet health industry in China through resource integration and complementary advantages [1][2] - The partnership aims to improve supply chain efficiency and business growth quality by optimizing cooperation models and enhancing brand performance in e-commerce channels [1][2] - JD Health has established a comprehensive pet health service ecosystem covering "medical, testing, pharmaceuticals, and insurance," with a significant increase in pet medicine sales [2] Group 1 - JD Health's strategic cooperation with Boehringer Ingelheim will leverage JD's "super pharmaceutical supply chain" and extensive medical service resources [1] - The collaboration will focus on all-channel supply chain, brand co-construction, and user service [1] - Boehringer Ingelheim's innovative oral external parasite control product, Fuweien, led the pet health category on JD Health for 21 consecutive days after its exclusive online launch [1] Group 2 - JD Health has the most comprehensive online pet medicine supply chain, covering 132 pet medicine approvals and core categories such as deworming and prescription drugs [2] - The platform has over 5,500 licensed veterinarians and offers online doctor education services to effectively communicate brand concepts and product advantages [2] - The partnership is expected to drive sales growth and optimize the pet health industry ecosystem [2] Group 3 - JD Health plans to continue collaborating with global pharmaceutical companies to enhance its pet health product and service matrix [3] - The focus will be on building an efficient and professional pet pharmaceutical distribution system [3] - The commitment to providing convenient and professional health solutions for pet-owning families will be upheld [3]